Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) have earned an average recommendation of “Hold” from the ...

Baird downgraded Carisma Therapeutics (CARM) to Neutral from Outperform with a price target of $1, down from $10. Carisma earlier this week announced plans to undergo a strategic restructuring ...

PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) announced a strategic realignment of its resources, discontinuing the development of its CT-0525 program and reducing its workforce by ...

In a report released yesterday, Justin Zelin from BTIG maintained a Hold rating on Carisma Therapeutics (CARM – Research Report). The company’s shares closed yesterday at $0.45. Discover ...

Carisma Therapeutics (NASDAQ:CARM – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a report released on Monday,Benzinga reports.

Carisma Therapeutics Inc. has entered into a master services agreement with Danforth Global, Inc. and Danforth Advisors, LLC to receive finance and accounting services from Natalie McAndrew ...

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Steven Kelly, President and Chief Executive Officer, will ...

Carisma Therapeutics Inc. (NASDAQ: CARM) shares are trading higher on Friday following the company's announcement of a significant development in its collaboration with Moderna.

Carisma Therapeutics (CARM) has filed for up to 3,730,608 share offering by selling stockholders.

PHILADELPHIA, Feb. 5, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today ...